Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | KEYNOTE-199: an update on pembrolizumab for mCRPC

Emmanuel Antonarakis • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Prostate Cancer Docetaxel Enzalutamide Olaparib Pembrolizumab
KEYNOTE-199

Emmanuel Antonarakis, MBBCh, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, gives us an update on the KEYNOTE-199 trial (NCT02787005), using pembrolizumab as monotherapy in men with metastatic castration-resistant prostate cancer (mCRPC), and the potential of combining pembrolizumab with docetaxel, enzalutamide or olaparib. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Emmanuel Antonarakis

3:56
PARP inhibitors: activity in BRCA1 versus BRCA2 altered mCRPC
Emmanuel Antonarakis • 12 Feb 2021
2:58
Characterization of PSA responses to bipolar androgen therapy in mCRPC
Emmanuel Antonarakis • 12 Feb 2021
1:46
Genomic and clinical features of SPOP mutations in prostate cancer
Emmanuel Antonarakis • 12 Feb 2021
4:34
Emerging treatments for mCRPC
Emmanuel Antonarakis • 13 Feb 2020

Related Videos

2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals